Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry
Authors:
- Annika KasprzakAnnika Kasprzak
- Julia AndresenJulia Andresen
- Kathrin NachtkampKathrin Nachtkamp
- Andrea KündgenAndrea Kündgen
- Felicitas SchulzFelicitas Schulz
- Corinna StruppCorinna Strupp
- Guido KobbeGuido Kobbe
- Colin MacKenzieColin MacKenzie
- Jörg TimmJörg Timm
- Sascha DietrichSascha Dietrich
- Norbert GattermannNorbert Gattermann
- Ulrich GermingUlrich Germing
Open Access
Abstract
Despite notable advancements in infection prevention and treatment, individuals with hematologic malignancies still face the persistent threat of frequent and life-threatening complications. Those undergoing chemotherapy or other disease-modifying therapies are particularly vulnerable to developing infectious complications, increasing the risk of mortality. Myelodysplastic syndromes (MDS) predominantly affect the elderly, with the incidence rising with age and peaking at around 70 years. Patients with MDS commonly present with unexplained low blood-cell counts, primarily anemia, and often experience varying degrees of neutropenia as the disease progresses. In our subsequent retrospective study involving 1593 patients from the Düsseldorf MDS Registry, we aimed at outlining the incidence of infections in MDS patients and identifying factors contributing to heightened susceptibility to infectious complications in this population.Keywords
This publication has 30 references indexed in Scilit:
- A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survivalLeukemia Research, 2021
- Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group StudyClinical Lymphoma Myeloma and Leukemia, 2019
- Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming itBlood Reviews, 2019
- Causes of death in 2877 patients with myelodysplastic syndromesAnnals of Hematology, 2016
- Myelodysplastic SyndromesMayo Clinic Proceedings, 2015
- Myelodysplastic syndromesThe Lancet, 2014
- Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter studyAmerican Journal of Hematology, 2012
- Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registryLeukemia Research, 2011
- Cause of death in patients with lower‐risk myelodysplastic syndromeCancer, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009